1
|
Hadjiyannis Y, Jones JM, Chibisov I, Kiss J, Gabert K, Sevcik J, Bakdash S, Binstock A, Kilonsky C, Parviainen K, Kaplan A. Successful management of maternal anti-PP1P k alloimmunization in pregnancy with therapeutic plasma exchange and intravenous immunoglobulin. J Clin Apher 2024; 39:e22120. [PMID: 38733134 DOI: 10.1002/jca.22120] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2024] [Revised: 03/25/2024] [Accepted: 04/25/2024] [Indexed: 05/13/2024]
Abstract
Anti-PP1PK alloimmunization is rare given ubiquitous P1PK expression. Prevention of recurrent miscarriages and hemolytic disease of the fetus and newborn (HDFN) in pregnant individuals with anti-PP1PK antibodies has relied upon individual reports. Here, we demonstrate the successful management of maternal anti-PP1PK alloimmunization in a 23-year-old, G2P0010, with therapeutic plasma exchange (TPE), intravenous immunoglobulin (IVIG), and monitoring of anti-PP1Pk titers. Twice-weekly TPE (1.5 plasma volume [PV], 5% albumin replacement) with weekly titers and IVIG (1 g/kg) was initiated at 9 weeks of gestation (WG). The threshold titer was ≥16. Weekly middle cerebral artery-peak systolic velocities (MCA-PSV) for fetal anemia monitoring was initiated at 16 WG. PVs were adjusted throughout pregnancy based on treatment schedule, titers, and available albumin. Antigen-negative, ABO-compatible RBCs were obtained through the rare donor program and directed donation. An autologous blood autotransfusion system was reserved for delivery. Titers decreased from 128 to 8 by 10 WG. MCA-PSV remained stable. At 24 WG, TPE decreased to once weekly. After titers increased to 32, twice-weekly TPE resumed at 27 WG. Induction of labor was scheduled at 38 WG. Vaginal delivery of a 2950 g neonate (APGAR score: 9, 9) occurred without complication (Cord blood: 1+ IgG DAT; Anti-PP1Pk eluted). Newborn hemoglobin and bilirubin were unremarkable. Discharge occurred postpartum day 2. Anti-PP1Pk alloimmunization is rare but associated with recurrent miscarriages and HDFN. With multidisciplinary care, a successful pregnancy is possible with IVIG and TPE adjusted to PV and titers. We also propose a patient registry and comprehensive management plan.
Collapse
Affiliation(s)
- Yannis Hadjiyannis
- Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
| | - Jennifer M Jones
- Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan, USA
| | - Irina Chibisov
- Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
- Transfusion, Vitalant, Northeast Division, Pittsburgh, Pennsylvania, USA
- Clinical Aphersis, Vitalant, Northeast Division, Pittsburgh, Pennsylvania, USA
| | - Joseph Kiss
- Transfusion, Vitalant, Northeast Division, Pittsburgh, Pennsylvania, USA
- Clinical Aphersis, Vitalant, Northeast Division, Pittsburgh, Pennsylvania, USA
- Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
| | - Kim Gabert
- Transfusion, Vitalant, Northeast Division, Pittsburgh, Pennsylvania, USA
| | - Joan Sevcik
- Clinical Aphersis, Vitalant, Northeast Division, Pittsburgh, Pennsylvania, USA
| | - Suzanne Bakdash
- Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
- Transfusion, Vitalant, Northeast Division, Pittsburgh, Pennsylvania, USA
- Clinical Aphersis, Vitalant, Northeast Division, Pittsburgh, Pennsylvania, USA
| | - Anna Binstock
- Department of Obstetrics, Gynecology and Reproductive Sciences, UPMC Magee-Women's Hospital, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
| | - Carolyn Kilonsky
- Clinical Aphersis, Vitalant, Northeast Division, Pittsburgh, Pennsylvania, USA
| | - Kristiina Parviainen
- Department of Obstetrics, Gynecology and Reproductive Sciences, UPMC Magee-Women's Hospital, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
| | - Alesia Kaplan
- Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
- Transfusion, Vitalant, Northeast Division, Pittsburgh, Pennsylvania, USA
- Clinical Aphersis, Vitalant, Northeast Division, Pittsburgh, Pennsylvania, USA
| |
Collapse
|
2
|
Pignalosa O, Vigorita E, Capuano M, Caruso S, Mastroianni A, De Martino S, Vaccaro G, Meomartini D, Nocera C. Treatment with plasma exchange of a pregnant woman with anti-PP1Pk alloimmunization: A case report. Transfus Apher Sci 2024; 63:103871. [PMID: 38245405 DOI: 10.1016/j.transci.2024.103871] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2023] [Revised: 01/08/2024] [Accepted: 01/08/2024] [Indexed: 01/22/2024]
Abstract
The histo-blood group antigens P, P1 and Pk are a closely related set of glycosphingolipid structures expressed by red blood cells and other tissues. None of these three characters is expressed on p cells, a null phenotype that arises in the context of homozygous mutation of the A4GALT gene. Subjects with p phenotype spontaneously develop a natural alloantibody named anti-PP1Pk, which is a mixture of IgG and IgM against P1, P and Pk. While anti-P1 is a weak cold antibody with poor clinical significance, anti-P and anti-Pk antibodies are potent haemolysins responsible for severe hemolytic transfusion reactions. The rare anti-PP1Pk alloantibodies are associated with recurrent spontaneous abortion in the first trimester of gestation. P and Pk antigens are expressed at high levels on the placenta and antibodies directed against both these structures are deleterious to placental trophoblasts. Here we describe the use of plasma exchange (PEX) in a nulliparous 39-year-old woman with anti-PP1Pk antibodies and a history of repeated spontaneous early abortions and hypofertility. The patient underwent apheresis starting from the third week throughout the pregnancy and a healthy child was delivered by cesarean section at 35 WG. The newborn required only phototherapy within a few days of life. We can state that an early treatment with the only PEX has proven to be effective and safe in the management of a fetomaternal P-incompatibility caused by a high anti-PP1Pk titer (256).
Collapse
Affiliation(s)
- O Pignalosa
- UOC Medicina Trasfusionale, Ospedale del Mare, ASL Napoli 1 Centro, Italy.
| | - E Vigorita
- UOC Medicina Trasfusionale, Ospedale del Mare, ASL Napoli 1 Centro, Italy
| | - M Capuano
- UOC Medicina Trasfusionale, Ospedale del Mare, ASL Napoli 1 Centro, Italy
| | - S Caruso
- UOC Medicina Trasfusionale, Ospedale del Mare, ASL Napoli 1 Centro, Italy
| | - A Mastroianni
- UOC Medicina Trasfusionale, Ospedale del Mare, ASL Napoli 1 Centro, Italy
| | - S De Martino
- UOC Medicina Trasfusionale, Ospedale del Mare, ASL Napoli 1 Centro, Italy
| | - G Vaccaro
- UOC Medicina Trasfusionale, Ospedale del Mare, ASL Napoli 1 Centro, Italy
| | - D Meomartini
- UOC Medicina Trasfusionale, Ospedale del Mare, ASL Napoli 1 Centro, Italy
| | - C Nocera
- UOC Medicina Trasfusionale, Ospedale del Mare, ASL Napoli 1 Centro, Italy
| |
Collapse
|
3
|
Liang S, Wu F, Deng ZH, Liang YL, Peng L, Su YQ. Naturally occurring anti-PP1P K in a Chinese individual with p phenotype: A case based on compound heterozygosity including one novel allele. Transfusion 2022; 62:2184-2187. [PMID: 36264119 DOI: 10.1111/trf.17101] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2022] [Revised: 08/03/2022] [Accepted: 08/20/2022] [Indexed: 11/29/2022]
Abstract
BACKGROUND The null phenotype in P1PK blood group, known as "p," is extremely rare in the whole world. Individuals of p phenotype spontaneously form anti-PP1PK isoantibody. Here, we report a case of p phenotype with naturally occurring anti-PP1PK isoantibodies in a Chinese individual. STUDY DESIGN AND METHODS Serology tests, containing alloantibodies screening and identification, were conducted to demonstrate the phenotype in P1PK blood group. The genotype of A4GALT gene was identified by haplotypes separation and sequencing. RESULTS The serological assay demonstrated the p phenotype of the proband, presenting with 1:64 titer of anti-PP1PK . The sequencing data revealed a compound heterozygote consisting of A4GALT*P1.01 with c.343A>T and a novel allele based on A4GALT*01N.05 with an addition polymorphism c.100G>A. The sequence of the novel allele has been submitted to GenBank and the accession number OM912503 was assigned. CONCLUSION Our study demonstrates a case of naturally occurring anti-PP1Pk in a Chinese individual with p phenotype, which is based on compound heterozygosity including one novel allele. As the proband is a young lady, monitoring the titer of anti-PP1PK and early initiation of medical intervention are essential after her pregnancy.
Collapse
Affiliation(s)
- Shuang Liang
- Shenzhen Institute of Transfusion Medicine, Shenzhen Blood Center, Shenzhen, China
| | - Fan Wu
- Shenzhen Institute of Transfusion Medicine, Shenzhen Blood Center, Shenzhen, China
| | - Zhi-Hui Deng
- Shenzhen Institute of Transfusion Medicine, Shenzhen Blood Center, Shenzhen, China
| | - Yan-Lian Liang
- Shenzhen Institute of Transfusion Medicine, Shenzhen Blood Center, Shenzhen, China
| | - Long Peng
- Shenzhen Institute of Transfusion Medicine, Shenzhen Blood Center, Shenzhen, China
| | - Yu-Qing Su
- Shenzhen Institute of Transfusion Medicine, Shenzhen Blood Center, Shenzhen, China
| |
Collapse
|
4
|
Bereznicka A, Mikolajczyk K, Czerwinski M, Kaczmarek R. Microbial lectome versus host glycolipidome: How pathogens exploit glycosphingolipids to invade, dupe or kill. Front Microbiol 2022; 13:958653. [PMID: 36060781 PMCID: PMC9437549 DOI: 10.3389/fmicb.2022.958653] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2022] [Accepted: 07/22/2022] [Indexed: 11/13/2022] Open
Abstract
Glycosphingolipids (GSLs) are ubiquitous components of the cell membranes, found across several kingdoms of life, from bacteria to mammals, including humans. GSLs are a subclass of major glycolipids occurring in animal lipid membranes in clusters named “lipid rafts.” The most crucial functions of GSLs include signal transduction and regulation as well as participation in cell proliferation. Despite the mainstream view that pathogens rely on protein–protein interactions to survive and thrive in their hosts, many also target the host lipids. In particular, multiple pathogens produce adhesion molecules or toxins that bind GSLs. Attachment of pathogens to cell surface receptors is the initial step in infections. Many mammalian pathogens have evolved to recognize GSL-derived receptors. Animal glycosphingolipidomes consist of multiple types of GSLs differing in terminal glycan and ceramide structures in a cell or tissue-specific manner. Interspecies differences in GSLs dictate host specificity as well as cell and tissue tropisms. Evolutionary pressure exerted by pathogens on their hosts drives changes in cell surface glycoconjugates, including GSLs, and has produced a vast number of molecules and interaction mechanisms. Despite that abundance, the role of GSLs as pathogen receptors has been largely overlooked or only cursorily discussed. In this review, we take a closer look at GSLs and their role in the recognition, cellular entry, and toxicity of multiple bacterial, viral and fungal pathogens.
Collapse
|
5
|
Mikolajczyk K, Sikora M, Hanus C, Kaczmarek R, Czerwinski M. One of the two N-glycans on the human Gb3/CD77 synthase is essential for its activity and allosterically regulates its function. Biochem Biophys Res Commun 2022; 617:36-41. [DOI: 10.1016/j.bbrc.2022.05.085] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2022] [Revised: 05/17/2022] [Accepted: 05/27/2022] [Indexed: 11/02/2022]
|
6
|
Bereznicka A, Mikolajczyk K, Szymczak-Kulus K, Kapczynska K, Majorczyk E, Modlinska A, Piasecki T, Kaczmarek R, Czerwinski M. Two Paralogous Gb3/CD77 Synthases in Birds Show Different Preferences for Their Glycoprotein and Glycosphingolipid Substrates. Int J Mol Sci 2021; 22:9761. [PMID: 34575935 PMCID: PMC8466213 DOI: 10.3390/ijms22189761] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2021] [Revised: 09/06/2021] [Accepted: 09/06/2021] [Indexed: 11/22/2022] Open
Abstract
Most glycosyltransferases show remarkable gross and fine substrate specificity, which is reflected in the old one enzyme-one linkage paradigm. While human Gb3/CD77 synthase is a glycosyltransferase that synthesizes the Galα1→4Gal moiety mainly on glycosphingolipids, its pigeon homolog prefers glycoproteins as acceptors. In this study, we characterized two Gb3/CD77 synthase paralogs found in pigeons (Columba livia). We evaluated their specificities in transfected human teratocarcinoma 2102Ep cells by flow cytofluorometry, Western blotting, high-performance thin-layer chromatography, mass spectrometry and metabolic labelling with 14C-galactose. We found that the previously described pigeon Gb3/CD77 synthase (called P) can use predominately glycoproteins as acceptors, while its paralog (called M), which we serendipitously discovered while conducting this study, efficiently synthesizes Galα1→4Gal caps on both glycoproteins and glycosphingolipids. These two paralogs may underlie the difference in expression profiles of Galα1→4Gal-terminated glycoconjugates between neoavians and mammals.
Collapse
Affiliation(s)
- Anna Bereznicka
- Laboratory of Glycobiology, Department of Immunochemistry, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 53-114 Wroclaw, Poland; (A.B.); (K.M.); (K.S.-K.); (R.K.)
| | - Krzysztof Mikolajczyk
- Laboratory of Glycobiology, Department of Immunochemistry, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 53-114 Wroclaw, Poland; (A.B.); (K.M.); (K.S.-K.); (R.K.)
| | - Katarzyna Szymczak-Kulus
- Laboratory of Glycobiology, Department of Immunochemistry, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 53-114 Wroclaw, Poland; (A.B.); (K.M.); (K.S.-K.); (R.K.)
| | - Katarzyna Kapczynska
- Laboratory of Medical Microbiology, Department of Immunology of Infectious Diseases, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 53-114 Wroclaw, Poland;
| | - Edyta Majorczyk
- Faculty of Physical Education and Physiotherapy, Opole University of Technology, 45-758 Opole, Poland;
| | - Anna Modlinska
- Department of Epizootiology and Clinic of Birds and Exotic Animals, Wroclaw University of Environmental Sciences, 50-366 Wroclaw, Poland; (A.M.); (T.P.)
| | - Tomasz Piasecki
- Department of Epizootiology and Clinic of Birds and Exotic Animals, Wroclaw University of Environmental Sciences, 50-366 Wroclaw, Poland; (A.M.); (T.P.)
| | - Radoslaw Kaczmarek
- Laboratory of Glycobiology, Department of Immunochemistry, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 53-114 Wroclaw, Poland; (A.B.); (K.M.); (K.S.-K.); (R.K.)
| | - Marcin Czerwinski
- Laboratory of Glycobiology, Department of Immunochemistry, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 53-114 Wroclaw, Poland; (A.B.); (K.M.); (K.S.-K.); (R.K.)
| |
Collapse
|
7
|
Qiu F, He M, Ma Y, Shen G. Novel A4GALT gene variation with rare p phenotype in a Chinese family. Transfusion 2021; 61:E57-E58. [PMID: 34314514 DOI: 10.1111/trf.16576] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2021] [Revised: 04/06/2021] [Accepted: 04/28/2021] [Indexed: 11/29/2022]
Affiliation(s)
- Fengwu Qiu
- Institute of Blood Transfusion of Hubei Province, Wuhan Blood Center, Wuhan, China
| | - Mingdi He
- Institute of Blood Transfusion of Hubei Province, Wuhan Blood Center, Wuhan, China
| | - Yan Ma
- Institute of Blood Transfusion of Hubei Province, Wuhan Blood Center, Wuhan, China
| | - Gang Shen
- Institute of Blood Transfusion of Hubei Province, Wuhan Blood Center, Wuhan, China
| |
Collapse
|
8
|
Zarrouk H, Kaabi H, Chaabane M, Halouani L, Hmida S. First successful pregnancy outcome after twelve abortions in a Tunisian-woman with the rare p phenotype. Transfus Clin Biol 2021; 28:283-286. [PMID: 34153474 DOI: 10.1016/j.tracli.2021.06.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2021] [Revised: 06/09/2021] [Accepted: 06/10/2021] [Indexed: 10/21/2022]
Abstract
INTRODUCTION Anti-PP1P k alloantibody, is produced in the serum of individuals with the rare p phenotype. It is associated with severe haemolytic transfusion reactions, recurrent spontaneous early abortions as well as haemolytic disease of the foetus and newborn. Anti-PP1P k alloimmunization in pregnancy differ from others in their physiopathology. It seems that the placenta would be the main target of anti-PP1P k antibody. CASE REPORT This report concerns a 35 year old female, with a history of a high incidence (12) of early and recurrent miscarriages. She was found to have the extremely rare p phenotype and anti-PP1P k antibody in her serum. Her 13th pregnancy was successfully managed by plasmapheresis. No substitution fluid was added. Oral hydration was recommended before and after the apheresis sessions. 12 plasmapheresis cycles were performed before a healthy term female infant weighing 3kg600g, was delivered by caesarean section at 38 weeks of gestation. CONCLUSION Plasmapheresis seems to be the treatment of choice in the management of anti-PP1P k fetomaternal incompatibilities. However in this case, we opted for an original and less expensive protocol. We did resort, neither to substitution fluid nor to intravenous immunoglobulin.
Collapse
Affiliation(s)
- H Zarrouk
- Immunohematology Laboratory National Center of Blood Transfusion, Tunis, Tunisia.
| | - H Kaabi
- Immunohematology Laboratory National Center of Blood Transfusion, Tunis, Tunisia
| | - M Chaabane
- Immunohematology Laboratory National Center of Blood Transfusion, Tunis, Tunisia
| | - L Halouani
- Private Hospital Les Jasmins, Tunis, Tunisia
| | - S Hmida
- Immunohematology Laboratory National Center of Blood Transfusion, Tunis, Tunisia
| |
Collapse
|
9
|
Mikolajczyk K, Bereznicka A, Szymczak-Kulus K, Haczkiewicz-Lesniak K, Szulc B, Olczak M, Rossowska J, Majorczyk E, Kapczynska K, Bovin N, Lisowska M, Kaczmarek R, Miazek A, Czerwinski M. Missing the sweet spot: one of the two N-glycans on human Gb3/CD77 synthase is expendable. Glycobiology 2021; 31:1145-1162. [PMID: 33978735 DOI: 10.1093/glycob/cwab041] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2021] [Revised: 04/23/2021] [Accepted: 04/29/2021] [Indexed: 02/07/2023] Open
Abstract
N-glycosylation is a ubiquitous posttranslational modification that may influence folding, subcellular localization, secretion, solubility and oligomerization of proteins. In this study, we examined the effects of N-glycans on the activity of human Gb3/CD77 synthase, which catalyzes the synthesis of glycosphingolipids with terminal Galα1 → 4Gal (Gb3 and the P1 antigen) and Galα1 → 4GalNAc disaccharides (the NOR antigen). The human Gb3/CD77 synthase contains two occupied N-glycosylation sites at positions N121 and N203. Intriguingly, we found that while the N-glycan at N203 is essential for activity and correct subcellular localization, the N-glycan at N121 is dispensable and its absence did not reduce, but, surprisingly, even increased the activity of the enzyme. The fully N-glycosylated human Gb3/CD77 synthase and its glycoform missing the N121 glycan correctly localized in the Golgi, whereas a glycoform without the N203 site partially mislocalized in the endoplasmic reticulum. A double mutein missing both N-glycans was inactive and accumulated in the endoplasmic reticulum. Our results suggest that the decreased specific activity of human Gb3/CD77 synthase glycovariants results from their improper subcellular localization and, to a smaller degree, a decrease in enzyme solubility. Taken together, our findings show that the two N-glycans of human Gb3/CD77 synthase have opposing effects on its properties, revealing a dual nature of N-glycosylation and potentially a novel regulatory mechanism controlling the biological activity of proteins.
Collapse
Affiliation(s)
- Krzysztof Mikolajczyk
- Laboratory of Glycobiology, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Rudolfa Weigla St. 12, 53-114 Wroclaw, Poland
| | - Anna Bereznicka
- Laboratory of Glycobiology, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Rudolfa Weigla St. 12, 53-114 Wroclaw, Poland
| | - Katarzyna Szymczak-Kulus
- Laboratory of Glycobiology, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Rudolfa Weigla St. 12, 53-114 Wroclaw, Poland
| | - Katarzyna Haczkiewicz-Lesniak
- Department of Ultrastructural Research, Faculty of Medicine, Wroclaw Medical University, Chalubinskiego St. 6a, 50-368, Wroclaw, Poland
| | - Bozena Szulc
- Faculty of Biotechnology, University of Wroclaw, Joliot-Curie St. 14A, 50-383 Wroclaw, Poland
| | - Mariusz Olczak
- Faculty of Biotechnology, University of Wroclaw, Joliot-Curie St. 14A, 50-383 Wroclaw, Poland
| | - Joanna Rossowska
- Flow Cytometry Core Facility, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Rudolfa Weigla St. 12, 53-114 Wroclaw, Poland
| | - Edyta Majorczyk
- Faculty of Physiotherapy and Physical Education, Opole University of Technology, Proszkowska St. 76, 45-758 Opole, Poland
| | - Katarzyna Kapczynska
- Department of Immunology of Infectious Diseases, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Rudolfa Weigla St. 12, 53-114 Wroclaw, Poland
| | - Nicolai Bovin
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry Russian Academy of Sciences, Miklukho-Maklaya St 16/10, Moscow 117997 Russia
| | - Marta Lisowska
- Department of Tumor Immunology, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Rudolfa Weigla St. 12, 53-114 Wroclaw, Poland
| | - Radoslaw Kaczmarek
- Laboratory of Glycobiology, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Rudolfa Weigla St. 12, 53-114 Wroclaw, Poland
| | - Arkadiusz Miazek
- Department of Tumor Immunology, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Rudolfa Weigla St. 12, 53-114 Wroclaw, Poland
| | - Marcin Czerwinski
- Laboratory of Glycobiology, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Rudolfa Weigla St. 12, 53-114 Wroclaw, Poland
| |
Collapse
|
10
|
Lépine MS, Goua V, Debouverie OS, Giraud C, Rafat C, Thonier V, Masmouhi BE, Ndour CT, Huguet-Jacquot S, Mailloux A, Cortey A, Jouannic JM, Maisonneuve E. Multidisciplinary management of anti-PP1P k or anti-P alloimmunization during pregnancy: A new case with anti-P and a literature review. Transfusion 2021; 61:1972-1979. [PMID: 33811650 DOI: 10.1111/trf.16384] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2020] [Accepted: 02/23/2021] [Indexed: 11/28/2022]
Abstract
BACKGROUND Red blood cell alloimmunization is the first cause of fetal and neonatal anemia. Alloimmunizations with anti-PP1Pk or anti-P can cause recurrent miscarriages and hemolytic disease of the fetus and newborn in the 2nd and 3rd trimesters of pregnancy. We report on a pregnant patient immunized with anti-P and a history of recurrent miscarriages. CASE REPORT This P2 k (GLOB:-1; P1PK:-1,3) patient had a first pregnancy marked by a caesarean at 38 weeks of gestation (WG) for non-reassuring fetal heart rate. Then, she had three early spontaneous miscarriages. The fifth pregnancy began with a high titer of anti-P at 128. Early initiation of treatment with Intravenous Immunoglobulins (IVIg) and plasma exchanges (PE) starting at 5 WG permitted us to reduce the titer of anti-P below 32. A healthy infant was delivered by caesarean at 38 WG without anemia at birth and no exchange transfusion was required. DISCUSSION AND REVIEW OF THE LITERATURE The P and Pk antigens are expressed on placental, trophoblastic, and embryonic cells. This explains why P1 k (GLOB:-1; P1PK:1,3), P2 k (GLOB:-1; P1PK:-1,3), or Tj(a-)/p (GLOB:-1; P1PK:-1,-3) patients are prone to recurrent abortions in the first trimester of pregnancy. A literature review demonstrated 87% (68/78) of miscarriages in p patients. However, publication biases are possible with the most severe cases being reported. CONCLUSION Immunizations to P and PP1Pk antigens differ from others in their physiopathology and precocity. The association of PE and IVIg seems to be an effective treatment in the management of anti-PP1Pk or anti-P fetomaternal incompatibilities.
Collapse
Affiliation(s)
- Marlène Sohier Lépine
- Department of Obstetrics and Gynecology, Poitiers University Hospital, Poitiers University, Poitiers, France
| | - Valérie Goua
- Department of Obstetrics and Gynecology, Poitiers University Hospital, Poitiers University, Poitiers, France
| | - Odile Souchaud Debouverie
- Department of Internal Medicine, Poitiers University Hospital, Poitiers University, Poitiers, France
| | - Christine Giraud
- Department of Hematology, Poitiers University Hospital, Poitiers University, Poitiers, France.,Établissement Français du Sang (EFS), Poitiers, France
| | - Cédric Rafat
- Department of Nephrology and Kidney Transplantation, Tenon Hospital, Paris, France
| | - Vincent Thonier
- Centre National de Référence pour les Groupes Sanguins (CNRGS), Paris, France.,Institut National de la Transfusion Sanguine (INTS), Paris, France
| | | | - Cécile Toly Ndour
- Department of Fetal Medicine, Trousseau Hospital, Paris, France.,Centre National de Référence en Hémobiologie Périnatale (CNRHP), Trousseau Hospital, Paris, France
| | - Stéphanie Huguet-Jacquot
- Department of Fetal Medicine, Trousseau Hospital, Paris, France.,Centre National de Référence en Hémobiologie Périnatale (CNRHP), Trousseau Hospital, Paris, France
| | - Agnès Mailloux
- Department of Fetal Medicine, Trousseau Hospital, Paris, France.,Centre National de Référence en Hémobiologie Périnatale (CNRHP), Trousseau Hospital, Paris, France
| | - Anne Cortey
- Department of Fetal Medicine, Trousseau Hospital, Paris, France.,Centre National de Référence en Hémobiologie Périnatale (CNRHP), Trousseau Hospital, Paris, France
| | - Jean-Marie Jouannic
- Department of Fetal Medicine, Trousseau Hospital, Paris, France.,Centre National de Référence en Hémobiologie Périnatale (CNRHP), Trousseau Hospital, Paris, France
| | - Emeline Maisonneuve
- Department of Fetal Medicine, Trousseau Hospital, Paris, France.,Centre National de Référence en Hémobiologie Périnatale (CNRHP), Trousseau Hospital, Paris, France
| |
Collapse
|
11
|
Szymczak-Kulus K, Weidler S, Bereznicka A, Mikolajczyk K, Kaczmarek R, Bednarz B, Zhang T, Urbaniak A, Olczak M, Park EY, Majorczyk E, Kapczynska K, Lukasiewicz J, Wuhrer M, Unverzagt C, Czerwinski M. Human Gb3/CD77 synthase produces P1 glycotope-capped N-glycans, which mediate Shiga toxin 1 but not Shiga toxin 2 cell entry. J Biol Chem 2021; 296:100299. [PMID: 33460651 PMCID: PMC7949097 DOI: 10.1016/j.jbc.2021.100299] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2020] [Revised: 01/07/2021] [Accepted: 01/12/2021] [Indexed: 12/15/2022] Open
Abstract
The human Gb3/CD77 synthase, encoded by the A4GALT gene, is an unusually promiscuous glycosyltransferase. It synthesizes the Galα1→4Gal linkage on two different glycosphingolipids (GSLs), producing globotriaosylceramide (Gb3, CD77, Pk) and the P1 antigen. Gb3 is the major receptor for Shiga toxins (Stxs) produced by enterohemorrhagic Escherichia coli. A single amino acid substitution (p.Q211E) ramps up the enzyme's promiscuity, rendering it able to attach Gal both to another Gal residue and to GalNAc, giving rise to NOR1 and NOR2 GSLs. Human Gb3/CD77 synthase was long believed to transfer Gal only to GSL acceptors, therefore its GSL products were, by default, considered the only human Stx receptors. Here, using soluble, recombinant human Gb3/CD77 synthase and p.Q211E mutein, we demonstrate that both enzymes can synthesize the P1 glycotope (terminal Galα1→4Galβ1→4GlcNAc-R) on a complex type N-glycan and a synthetic N-glycoprotein (saposin D). Moreover, by transfection of CHO-Lec2 cells with vectors encoding human Gb3/CD77 synthase and its p.Q211E mutein, we demonstrate that both enzymes produce P1 glycotopes on N-glycoproteins, with the mutein exhibiting elevated activity. These P1-terminated N-glycoproteins are recognized by Stx1 but not Stx2 B subunits. Finally, cytotoxicity assays show that Stx1 can use P1 N-glycoproteins produced in CHO-Lec2 cells as functional receptors. We conclude that Stx1 can recognize and use P1 N-glycoproteins in addition to its canonical GSL receptors to enter and kill the cells, while Stx2 can use GSLs only. Collectively, these results may have important implications for our understanding of the Shiga toxin pathology.
Collapse
Affiliation(s)
- Katarzyna Szymczak-Kulus
- Laboratory of Glycobiology, Hirszfeld Institute of Immunology and Experimental Therapy, Wroclaw, Poland
| | - Sascha Weidler
- Department of Bioorganic Chemistry, University of Bayreuth, Bayreuth, Germany
| | - Anna Bereznicka
- Laboratory of Glycobiology, Hirszfeld Institute of Immunology and Experimental Therapy, Wroclaw, Poland
| | - Krzysztof Mikolajczyk
- Laboratory of Glycobiology, Hirszfeld Institute of Immunology and Experimental Therapy, Wroclaw, Poland
| | - Radoslaw Kaczmarek
- Laboratory of Glycobiology, Hirszfeld Institute of Immunology and Experimental Therapy, Wroclaw, Poland
| | - Bartosz Bednarz
- Laboratory of Molecular Biology of Microorganisms, Hirszfeld Institute of Immunology and Experimental Therapy, Wroclaw, Poland
| | - Tao Zhang
- Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, The Netherlands
| | - Anna Urbaniak
- Department of Biochemistry and Molecular Biology, Faculty of Veterinary Medicine, Wroclaw University of Environmental and Life Sciences, Wroclaw, Poland
| | - Mariusz Olczak
- Department of Biochemistry, Faculty of Biotechnology, University of Wroclaw, Wroclaw, Poland
| | - Enoch Y Park
- Laboratory of Biotechnology, Shizuoka University, Shizuoka, Japan
| | - Edyta Majorczyk
- Faculty of Physical Education and Physiotherapy, Opole University of Technology, Opole, Poland
| | - Katarzyna Kapczynska
- Laboratory of Medical Microbiology, Hirszfeld Institute of Immunology and Experimental Therapy, Wroclaw, Poland
| | - Jolanta Lukasiewicz
- Laboratory of Microbial Immunochemistry and Vaccines, Hirszfeld Institute of Immunology and Experimental Therapy, Wroclaw, Poland
| | - Manfred Wuhrer
- Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, The Netherlands
| | - Carlo Unverzagt
- Department of Bioorganic Chemistry, University of Bayreuth, Bayreuth, Germany
| | - Marcin Czerwinski
- Laboratory of Glycobiology, Hirszfeld Institute of Immunology and Experimental Therapy, Wroclaw, Poland.
| |
Collapse
|
12
|
Di Ciaccio P, Cutts B, Alahakoon TI, Dennington PM, Soo LA, Curnow J. Clinical consequences of the extremely rare anti-PP1Pk isoantibodies in pregnancy: a case series and review of the literature. Vox Sang 2020; 116:591-600. [PMID: 33326620 DOI: 10.1111/vox.13042] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2020] [Revised: 11/12/2020] [Accepted: 11/15/2020] [Indexed: 01/26/2023]
Abstract
BACKGROUND The absence of the red cell antigens P, P1 and Pk , known as 'p', represents an extremely rare red cell phenotype. Individuals with this phenotype spontaneously form anti-PP1Pk isoantibodies, associated with severe haemolytic transfusion reactions, recurrent spontaneous abortion and haemolytic disease of the fetus and newborn (HDFN). METHODS We report a series of four successful pregnancies in three women with anti-PP1Pk isoantibodies, one complicated by HDFN, another by intrauterine growth restriction, all managed supportively. We also review the literature regarding the management of pregnancy involving anti-PP1Pk isoimmunization. RESULTS The literature surrounding anti-PP1Pk in pregnancy is limited to a very small number of case reports. The majority report management with therapeutic plasma exchange (TPE) with or without intravenous immunoglobulin. The relationship between titre and risk of pregnancy loss remains unclear, though a history of recurrent pregnancy loss appears important. Although a positive cord blood direct antiglobulin test is frequently noted, clinically significant HDFN appears uncommon, though possible. CONCLUSION Early initiation of TPE in high risk patients should be strongly considered. If possible, pregnancies should be managed in a high-risk obstetric or maternal fetal medicine service. The fetus should be monitored closely with interval fetal ultrasound and middle cerebral artery peak systolic volume Doppler to screen for fetal anaemia. Timely sourcing of compatible blood products is likely to be highly challenging, and both directed and autologous donation should be contemplated where appropriate. The International Red Cell Donor Panel may also provide access to compatible products.
Collapse
Affiliation(s)
- Pietro Di Ciaccio
- Department of Haematology, Westmead Hospital, Sydney, NSW, Australia
| | - Briony Cutts
- Department of Haematology, The Royal Women's Hospital, Melbourne, VIC, Australia
| | | | | | - Luke A Soo
- Australian Red Cross Lifeblood, Sydney, NSW, Australia
| | - Jennifer Curnow
- Department of Haematology, Westmead Hospital, Sydney, NSW, Australia
| |
Collapse
|
13
|
Thinley J, Nathalang O, Chidtrakoon S, Intharanut K. Blood group P1 prediction using multiplex PCR genotyping of A4GALT among Thai blood donors. Transfus Med 2020; 31:48-54. [PMID: 33314439 DOI: 10.1111/tme.12749] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2020] [Revised: 11/18/2020] [Accepted: 12/06/2020] [Indexed: 11/29/2022]
Abstract
OBJECTIVES This study aimed to investigate single-nucleotide variants (SNVs) associated with P1 expression among Thai blood donors and develop a genotyping method using multiplex polymerase chain reaction (PCR) to predict P1 blood group status. BACKGROUND The α1,4-galactosyltransferase (A4GALT), also called Gb3/CD77 synthase or P1/Pk synthase enzyme, is encoded by the A4GALT gene and catalyses the transfer of galactose from uridine diphosphate-galactose to lactosylceramide, creating the Pk antigen (Gb3). The same enzyme synthesises the P1 antigen by adding terminal galactose to paragloboside. The A4GALT transcripts are elevated in P1 , and different SNVs in transcription factor-binding regions of A4GALT correlate with P1 and P2 phenotypes. MATERIAL AND METHODS A total of 218 blood samples from Thai blood donors at the Thammasat University Hospital were tested for the P1 antigen using the conventional tube technique. Genomic DNA was extracted, and non-coding regions of A4GALT were sequenced and analysed. A multiplex PCR assay was developed and validated to identify P1-associated SNVs and was subsequently tested on 1022 Thai DNA samples of unknown P1 antigen status. RESULTS In the tested cohort (n = 218), P1 and P2 phenotypes were found in 24.77% and 75.23% of donors, respectively. Moreover, three SNVs-rs8138197 (C/T), rs2143918 (T/G) and rs5751348 (G/T)-correlated 100% with both phenotypes. Finally, findings agreed with serological phenotyping and DNA sequencing results, confirming their validity for predicting P1 antigen positivity. CONCLUSIONS This study confirmed that three SNVs also correlated with P1 /P2 phenotypes among Thais, as expected. A multiplex PCR found that SNVs rs2143918 (T) and rs5751348 (G) predicted blood group P1 and is an accurate, reproducible, cost-effective and less time-consuming alternative to traditional methods.
Collapse
Affiliation(s)
- Jigme Thinley
- Graduate Program in Biomedical Sciences, Faculty of Allied Health Sciences, Thammasat University, Pathumtani, Thailand
| | - Oytip Nathalang
- Graduate Program in Biomedical Sciences, Faculty of Allied Health Sciences, Thammasat University, Pathumtani, Thailand
| | | | - Kamphon Intharanut
- Graduate Program in Biomedical Sciences, Faculty of Allied Health Sciences, Thammasat University, Pathumtani, Thailand
| |
Collapse
|
14
|
Chen Q, Xiao J, Duan Z, Shi L, Huang C, Li M. Novel A4GALT gene variation with rare p phenotype in a compound heterozygous Chinese individual. Transfusion 2020; 61:E5-E6. [PMID: 33111355 DOI: 10.1111/trf.16163] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2020] [Revised: 08/29/2020] [Accepted: 09/07/2020] [Indexed: 11/26/2022]
Affiliation(s)
- Qing Chen
- Jiangsu Province Blood Center, Nanjing, China.,Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China
| | - Jianyu Xiao
- Jiangsu Province Blood Center, Nanjing, China
| | - Zhimin Duan
- Institute of Dermatology, Chinese Academy of Medical Science & Peking Union Medical College, Nanjing, China
| | - Lili Shi
- Jiangsu Province Blood Center, Nanjing, China
| | | | - Min Li
- Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China.,Institute of Dermatology, Chinese Academy of Medical Science & Peking Union Medical College, Nanjing, China
| |
Collapse
|
15
|
Ferreira S, Mourato C, Corpuz A, Galvão S, Hesse C, Rocha C, Jesus C, Mendes F. FORSCells: 40-days fixed prepared reagent for detection of anti-Forssman in humans. J Immunol Methods 2019; 478:112722. [PMID: 31816281 DOI: 10.1016/j.jim.2019.112722] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2019] [Revised: 11/27/2019] [Accepted: 12/05/2019] [Indexed: 11/30/2022]
Abstract
In 2012, the FORS system was accepted by the International Society of Blood Transfusion as the 31st blood group system. Forssman (Fs) antigen (Ag) expression is most commonly found on sheep red blood cells (RBC) but rare in human RBC. Anti-Fs antibodies (Ab) are naturally occurring in human sera and are predominantly IgM but they can also be IgG. To this day, the global prevalence of the FORS system is unknown. Currently, there is a lack of natural FORS1-positive RBC available to use for anti-Fs screening in large populations. This study was designed to produce FORS1-positive cells viable for 40 days use in the anti-Fs screening. Three to 5% FORS1-positive cells were produced using sheep's blood and CellStab stabilizer solution. The quality of the FORS1-positive cells was investigated in more than three independent experiments of ABO titration, osmotic fragility test and supernatant haemolysis. For each batch of FORS1-positive cells produced, an extended antibody panel was performed. To demonstrate that the FORS1-positive cells can be used for up to 40 days, anti-Fs screening and classification were carried out in a patient and donor population. Antigenic expression and membrane integrity of FORS1-positive cells remained stable for 40 days. Good FORS1 Ag preservation was established, and minimal haemolysis was observed. In conclusion, a novel and easy-to-produce reagent has been developed and submitted to a patent with stable FORS1 Ag expression. With this FORS1-positive cell suspension, it is now possible to screen and classify anti-Fs Ab in large populations.
Collapse
Affiliation(s)
- Sofia Ferreira
- Polytechnic of Coimbra, ESTeSC, Departament of Biomedical Laboratory Sciences, ESTeSC, Rua 5 de Outubro, SM Bispo, Apartado 7006, 3046-854, Coimbra, Portugal
| | - Cristiana Mourato
- Polytechnic of Coimbra, ESTeSC, Departament of Biomedical Laboratory Sciences, ESTeSC, Rua 5 de Outubro, SM Bispo, Apartado 7006, 3046-854, Coimbra, Portugal
| | - Alyssa Corpuz
- School of Biological Sciences, Dublin Institute of Technology, Kevin St, Dublin 8, Ireland
| | - Sofia Galvão
- Polytechnic of Coimbra, ESTeSC, Departament of Biomedical Laboratory Sciences, ESTeSC, Rua 5 de Outubro, SM Bispo, Apartado 7006, 3046-854, Coimbra, Portugal
| | - Camilla Hesse
- Institutionen för biomedicin, Sahlgrenska Akademin vid, Göteborgs Universitet, Sweden
| | - Clara Rocha
- Polytechnic of Coimbra, ESTeSC, Department Complementary Sciences, ESTeSC, Rua 5 de Outubro, SM Bispo, Apartado 7006, 3046-854, Coimbra, Portugal; Institute for Systems Engineering and Computers at Coimbra, Coimbra, Portugal
| | - Carlos Jesus
- Polytechnic of Coimbra, ESTeSC, Departament of Biomedical Laboratory Sciences, ESTeSC, Rua 5 de Outubro, SM Bispo, Apartado 7006, 3046-854, Coimbra, Portugal
| | - Fernando Mendes
- Polytechnic of Coimbra, ESTeSC, Departament of Biomedical Laboratory Sciences, ESTeSC, Rua 5 de Outubro, SM Bispo, Apartado 7006, 3046-854, Coimbra, Portugal; Biophysics Institute, Coimbra Institute for Clinical and Biomedical Research (iCBR) area of Environment Genetics and Oncobiology (CIMAGO), Faculty of Medicine, University of Coimbra, Azinhaga de Santa Comba, Celas, 3000-548 Coimbra, Portugal; CNC.IBILI Consortium/Center for Innovative Biomedicine and Biotechnology (CIBB), University of Coimbra, Azinhaga de Santa Comba, Celas, 3000-548 Coimbra, Portugal.
| |
Collapse
|
16
|
Lv X, Chen Y, Luo Y, Li L, Wang H. The synonymous 903C>G mutation in the alpha 1,4-galactosyltransferase gene in a Chinese woman with habitual abortion: A case report. Medicine (Baltimore) 2019; 98:e16361. [PMID: 31374005 PMCID: PMC6709120 DOI: 10.1097/md.0000000000016361] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
RATIONALE Habitual abortion is caused by complex and diverse factors, such as genetic factors, immune factors, endocrine factors, viruses, bacterial infections, and so on. Allogeneic antibodies, generated due to blood-group incompatibilities between a female and her fetus, are sometimes important for habitual abortion. PATIENT CONCERNS A 26-year-old woman had undergone abortions 3 times in July 2015 (17 weeks pregnant), March 2017 (15 weeks of gestation) and February 2018 (16 weeks pregnant) before she came to the Reproductive Medicine Center of our hospital for prenatal examinations without pregnancy. DIAGNOSES Unexplained habitual abortion. INTERVENTIONS A series of serological tests and nucleotide sequence of 1,4-galactosyltransferase (A4GALT) gene were performed. OUTCOMES The patient was the rare p phenotype in P1P blood system and the patient's habitual abortion was caused by anti-PP1P antibody which was generated naturally in persons with p phenotype. There was a mutation (903C>G, CCC>CCG) in the 3rd exon of A4GALT gene, which is likely a significant contributor to p phenotype. LESSONS This is the first case of habitual abortion caused by p phenotype due to independent 903C>G homozygous mutation with no similar record reported before, which indicates that it is a new class of mutation that leads to p phenotype.
Collapse
Affiliation(s)
- Xiaoying Lv
- Department of Clinical Laboratory, No.174 Hospital of Chinese People's Liberation Army/Chenggong Hospital Affiliated to Xiamen University/174 Clinical College of Anhui Medical University
| | - Yongquan Chen
- Department of Clinical Laboratory, Xiamen Humanity Hospital
| | - Yuanyuan Luo
- Department of Blood Transfusion, Xiamen Maternal and Child Health Hospital, Xiamen, Fujian
| | - Lingbo Li
- Changchun Bioxun Biotechnology Limited Liability Company, Changchun, Jilin, China
| | - Houzhao Wang
- Department of Clinical Laboratory, No.174 Hospital of Chinese People's Liberation Army/Chenggong Hospital Affiliated to Xiamen University/174 Clinical College of Anhui Medical University
| |
Collapse
|
17
|
Manaresi E, Gallinella G. Advances in the Development of Antiviral Strategies against Parvovirus B19. Viruses 2019; 11:v11070659. [PMID: 31323869 PMCID: PMC6669595 DOI: 10.3390/v11070659] [Citation(s) in RCA: 31] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2019] [Revised: 07/16/2019] [Accepted: 07/17/2019] [Indexed: 12/11/2022] Open
Abstract
Parvovirus B19 (B19V) is a human pathogenic virus, responsible for an ample range of clinical manifestations. Infections are usually mild, self-limiting, and controlled by the development of a specific immune response, but in many cases clinical situations can be more complex and require therapy. Presently available treatments are only supportive, symptomatic, or unspecific, such as administration of intravenous immunoglobulins, and often of limited efficacy. The development of antiviral strategies against B19V should be considered of highest relevance for increasing the available options for more specific and effective therapeutic treatments. This field of research has been explored in recent years, registering some achievements as well as interesting future perspectives. In addition to immunoglobulins, some compounds have been shown to possess inhibitory activity against B19V. Hydroxyurea is an antiproliferative drug used in the treatment of sickle-cell disease that also possesses inhibitory activity against B19V. The nucleotide analogues Cidofovir and its lipid conjugate Brincidofovir are broad-range antivirals mostly active against dsDNA viruses, which showed an antiviral activity also against B19V. Newly synthesized coumarin derivatives offer possibilities for the development of molecules with antiviral activity. Identification of some flavonoid molecules, with direct inhibitory activity against the viral non-structural (NS) protein, indicates a possible line of development for direct antiviral agents. Continuing research in the field, leading to better knowledge of the viral lifecycle and a precise understanding of virus–cell interactions, will offer novel opportunities for developing more efficient, targeted antiviral agents, which can be translated into available therapeutic options.
Collapse
Affiliation(s)
- Elisabetta Manaresi
- Department of Pharmacy and Biotechnology, University of Bologna, I-40138 Bologna, Italy
| | - Giorgio Gallinella
- Department of Pharmacy and Biotechnology, University of Bologna, I-40138 Bologna, Italy.
| |
Collapse
|
18
|
Wu H, Li G, Tang Q, Tian L, Liu Q, Zhou X, He H, Xiong L. The mutation and one-base insertion of the α(1,4)galactosyltransferase gene responsible for the p phenotype. Transfus Clin Biol 2018; 26:358-360. [PMID: 30361135 DOI: 10.1016/j.tracli.2018.08.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2018] [Accepted: 08/02/2018] [Indexed: 11/20/2022]
Affiliation(s)
- H Wu
- Institute of Blood Transfusion, Jiangxi Province Blood Center, Nanchang, Jiangxi 330077, People's Republic of China.
| | - G Li
- Institute of Blood Transfusion, Jiangxi Province Blood Center, Nanchang, Jiangxi 330077, People's Republic of China
| | - Q Tang
- Institute of Blood Transfusion, Jiangxi Province Blood Center, Nanchang, Jiangxi 330077, People's Republic of China
| | - L Tian
- Institute of Blood Transfusion, Chinese Academy of Medical Sciences, Chengdu 610052, People's Republic of China
| | - Q Liu
- Institute of Blood Transfusion, Jiangxi Province Blood Center, Nanchang, Jiangxi 330077, People's Republic of China
| | - X Zhou
- Institute of Blood Transfusion, Jiangxi Province Blood Center, Nanchang, Jiangxi 330077, People's Republic of China
| | - H He
- Institute of Blood Transfusion, Jiangxi Province Blood Center, Nanchang, Jiangxi 330077, People's Republic of China
| | - L Xiong
- Institute of Blood Transfusion, Jiangxi Province Blood Center, Nanchang, Jiangxi 330077, People's Republic of China
| |
Collapse
|
19
|
Kaczmarek R, Szymczak-Kulus K, Bereźnicka A, Mikołajczyk K, Duk M, Majorczyk E, Krop-Watorek A, Klausa E, Skowrońska J, Michalewska B, Brojer E, Czerwinski M. Single nucleotide polymorphisms in A4GALT spur extra products of the human Gb3/CD77 synthase and underlie the P1PK blood group system. PLoS One 2018; 13:e0196627. [PMID: 29709005 PMCID: PMC5927444 DOI: 10.1371/journal.pone.0196627] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2018] [Accepted: 04/16/2018] [Indexed: 02/06/2023] Open
Abstract
Contrary to the mainstream blood group systems, P1PK continues to puzzle and generate controversies over its molecular background. The P1PK system comprises three glycosphingolipid antigens: Pk, P1 and NOR, all synthesised by a glycosyltransferase called Gb3/CD77 synthase. The Pk antigen is present in most individuals, whereas P1 frequency is lesser and varies regionally, thus underlying two common phenotypes: P1, if the P1 antigen is present, and P2, when P1 is absent. Null and NOR phenotypes are extremely rare. To date, several single nucleotide polymorphisms (SNPs) have been proposed to predict the P1/P2 status, but it has not been clear how important they are in general and in relation to each other, nor has it been clear how synthesis of NOR affects the P1 phenotype. Here, we quantitatively analysed the phenotypes and A4GALT transcription in relation to the previously proposed SNPs in a sample of 109 individuals, and addressed potential P1 antigen level confounders, most notably the red cell membrane cholesterol content. While all the SNPs were associated with the P1/P2 blood type and rs5751348 was the most reliable, we found large differences in P1 level within groups defined by their genotype and substantial intercohort overlaps, which shows that the P1PK blood group system still eludes full understanding.
Collapse
Affiliation(s)
- Radoslaw Kaczmarek
- Laboratory of Glycobiology, Hirszfeld Institute of Immunology and Experimental Therapy, Wroclaw, Poland
- * E-mail:
| | - Katarzyna Szymczak-Kulus
- Laboratory of Glycobiology, Hirszfeld Institute of Immunology and Experimental Therapy, Wroclaw, Poland
| | - Anna Bereźnicka
- Laboratory of Glycobiology, Hirszfeld Institute of Immunology and Experimental Therapy, Wroclaw, Poland
| | - Krzysztof Mikołajczyk
- Laboratory of Glycobiology, Hirszfeld Institute of Immunology and Experimental Therapy, Wroclaw, Poland
| | - Maria Duk
- Laboratory of Glycobiology, Hirszfeld Institute of Immunology and Experimental Therapy, Wroclaw, Poland
| | - Edyta Majorczyk
- Faculty of Physical Education and Physiotherapy, Opole University of Technology, Opole, Poland
| | - Anna Krop-Watorek
- Department of Biotechnology and Molecular Biology, University of Opole, Opole, Poland
| | - Elżbieta Klausa
- Regional Centre of Transfusion Medicine and Blood Bank, Wroclaw, Poland
| | - Joanna Skowrońska
- Regional Centre of Transfusion Medicine and Blood Bank, Katowice, Poland
| | - Bogumiła Michalewska
- Department of Immunohaematology and Immunology of Transfusion Medicine, Institute of Haematology and Blood Transfusion, Warsaw, Poland
| | - Ewa Brojer
- Department of Immunohaematology and Immunology of Transfusion Medicine, Institute of Haematology and Blood Transfusion, Warsaw, Poland
| | - Marcin Czerwinski
- Laboratory of Glycobiology, Hirszfeld Institute of Immunology and Experimental Therapy, Wroclaw, Poland
- Faculty of Physical Education and Physiotherapy, Opole University of Technology, Opole, Poland
| |
Collapse
|
20
|
Montavon Sartorius C, Schoetzau A, Kettelhack H, Fink D, Hacker NF, Fedier A, Jacob F, Heinzelmann-Schwarz V. ABO blood groups as a prognostic factor for recurrence in ovarian and vulvar cancer. PLoS One 2018; 13:e0195213. [PMID: 29596526 PMCID: PMC5875852 DOI: 10.1371/journal.pone.0195213] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2017] [Accepted: 03/04/2018] [Indexed: 12/20/2022] Open
Abstract
The relationship between ABO blood groups (BG) and risk of incidence in cancers including gynecological cancers has been widely studied, showing increased incidence risk for BG A patients. As available data are inconsistent we investigated whether BG and their anti-glycan antibodies (anti-A and anti-B) have prognostic values in gynecological cancers. We retrospectively evaluated 974 patients with gynecological cancers in three cancer centers (Switzerland and Australia) between 1974 and 2014 regarding the relationships between clinico-pathological findings and the BG. Time to disease recurrence was significantly influenced by BG in patients with ovarian (n = 282) and vulvar (n = 67) cancer. BG O or B patients showed a significantly increased risk for ovarian cancer relapse compared to A, 59% and 82%, respectively (p = 0.045; HR O vs A = 1.59 (CI 1.01-2.51) and (p = 0.036; HR A vs B = 0.55 (CI 0.32-0.96). Median time to relapse for advanced stage (n = 126) ovarian cancer patients was 18.2 months for BG O and 32.2 for A (p = 0.031; HR O vs A = 2.07 (CI 1.07-4.02)). BG also significantly influenced relapse-free survival in patients with vulvar cancer (p = 0.002), with BG O tending to have increased relapse risk compared to A (p = 0.089). Blood groups hence associate with recurrence in ovarian and vulvar cancer: women with BG O seem to have a lower ovarian cancer incidence, however are more likely to relapse earlier. The significance of the BG status as a prognostic value is evident and may be helpful to oncologists in prognosticating disease outcome and selecting the appropriate therapy.
Collapse
Affiliation(s)
- Céline Montavon Sartorius
- Department of Gynecology and Gynecological Oncology, Hospital for Women, University Hospital Basel and University of Basel, Basel, Switzerland
| | - Andreas Schoetzau
- Ovarian Cancer Research, Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland
| | - Henriette Kettelhack
- Ovarian Cancer Research, Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland
| | - Daniel Fink
- Department of Gynecology, University Hospital Zurich and University of Zurich, Zurich, Switzerland
| | - Neville F. Hacker
- Gynaecological Cancer Center, Royal Hospital for Women, School of Women’s and Children’s Health, UNSW, Sydney, Australia
| | - André Fedier
- Ovarian Cancer Research, Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland
| | - Francis Jacob
- Ovarian Cancer Research, Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland
- Glyco-Oncology Research, Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland
| | - Viola Heinzelmann-Schwarz
- Department of Gynecology and Gynecological Oncology, Hospital for Women, University Hospital Basel and University of Basel, Basel, Switzerland
- Ovarian Cancer Research, Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland
- * E-mail:
| |
Collapse
|
21
|
Yeh CC, Chang CJ, Twu YC, Hung ST, Tsai YJ, Liao JC, Huang JT, Kao YH, Lin SW, Yu LC. The differential expression of the blood group P1
-A4GALT
and P2
-A4GALT
alleles is stimulated by the transcription factor early growth response 1. Transfusion 2018; 58:1054-1064. [DOI: 10.1111/trf.14515] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2017] [Revised: 11/29/2017] [Accepted: 12/20/2017] [Indexed: 12/18/2022]
Affiliation(s)
- Chih-Chun Yeh
- Institute of Biochemical Sciences, College of Life Science, National Taiwan University; Taipei Taiwan
| | - Ching-Jin Chang
- Institute of Biochemical Sciences, College of Life Science, National Taiwan University; Taipei Taiwan
- Institute of Biological Chemistry, Academia Sinica; Taipei Taiwan
| | - Yuh-Ching Twu
- Department of Biotechnology and Laboratory Science in Medicine; School of Biomedical Science and Engineering, National Yang-Ming University; Taipei Taiwan
| | - Shu-Ting Hung
- Institute of Biochemical Sciences, College of Life Science, National Taiwan University; Taipei Taiwan
| | - Yi-Jui Tsai
- Institute of Biochemical Sciences, College of Life Science, National Taiwan University; Taipei Taiwan
| | - Jia-Ching Liao
- Institute of Biochemical Sciences, College of Life Science, National Taiwan University; Taipei Taiwan
| | - Ji-Ting Huang
- Institute of Biochemical Sciences, College of Life Science, National Taiwan University; Taipei Taiwan
| | - Yu-Hsin Kao
- Institute of Biochemical Sciences, College of Life Science, National Taiwan University; Taipei Taiwan
| | - Sheng-Wei Lin
- Institute of Biological Chemistry, Academia Sinica; Taipei Taiwan
| | - Lung-Chih Yu
- Institute of Biochemical Sciences, College of Life Science, National Taiwan University; Taipei Taiwan
- Institute of Biological Chemistry, Academia Sinica; Taipei Taiwan
| |
Collapse
|
22
|
Kaczmarek R, Pasciak M, Szymczak-Kulus K, Czerwinski M. CD1: A Singed Cat of the Three Antigen Presentation Systems. Arch Immunol Ther Exp (Warsz) 2017; 65:201-214. [PMID: 28386696 PMCID: PMC5434122 DOI: 10.1007/s00005-017-0461-y] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2016] [Accepted: 02/20/2017] [Indexed: 02/07/2023]
Abstract
Contrary to general view that the MHC Class I and II are the kapellmeisters of recognition and response to antigens, there is another big player in that part of immunity, represented by CD1 glycoproteins. In contrast to MHC Class I or II, which present peptides, CD1 molecules present lipids. Humans express five CD1 proteins (CD1a-e), four of which (CD1a-d) are trafficked to the cell surface, where they may display lipid antigens to T-cell receptors. This interaction may lead to both non-cognate and cognate T cell help to B cells, the latter eliciting anti-lipid antibody response. All CD1 proteins can bind a broad range of structurally different exogenous and endogenous lipids, but each shows a preference to one or more lipid classes. This unorthodox binding behavior is the result of elaborate architectures of CD1 binding clefts and distinct intracellular trafficking routes. Together, these features make CD1 system a versatile player in immune response, sitting at the crossroads of innate and adaptive immunity. While CD1 system may be involved in numerous infectious, inflammatory, and autoimmune diseases, its involvement may lead to opposite outcomes depending on different pathologies. Despite these ambiguities and complexity, CD1 system draws growing attention and continues to show glimmers of therapeutic potential. In this review, we summarize the current knowledge about CD1 proteins, their structures, lipid-binding profiles, and roles in immunity, and evaluate the role of CD1 proteins in eliciting humoral immune response.
Collapse
Affiliation(s)
- Radoslaw Kaczmarek
- Laboratory of Glycoconjugate Immunochemistry, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland
| | - Mariola Pasciak
- Laboratory of Medical Microbiology, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland
| | - Katarzyna Szymczak-Kulus
- Laboratory of Glycoconjugate Immunochemistry, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland
| | - Marcin Czerwinski
- Laboratory of Glycoconjugate Immunochemistry, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland. .,Faculty of Physiotherapy and Physical Education, Opole University of Technology, Opole, Poland.
| |
Collapse
|
23
|
Reeves HM, Cary V, Mino MA, McGrath C, Westra JA, Piccone C, Downes KA. Unexpected Non-Maternally Derived Anti-PP1P k in an 11-Week-Old Patient. J Pediatr 2017; 181:302-305. [PMID: 27852457 DOI: 10.1016/j.jpeds.2016.10.042] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/02/2016] [Revised: 07/18/2016] [Accepted: 10/11/2016] [Indexed: 11/16/2022]
Abstract
Alloantibody formation at less than 4 months of age is rare. Most antibodies identified in these patients are maternally derived. Anti-PP1Pk was detected in an 11-week-old infant that was not maternally derived. A multidisciplinary team approach led to appropriate testing, diagnosis, and transfusion management in this critically ill infant.
Collapse
Affiliation(s)
- Hollie M Reeves
- Department of Pathology, University Hospitals Cleveland Medical Center, Rainbow Babies and Children's Hospital, Case Western Reserve University School of Medicine, Cleveland, OH.
| | - Victoria Cary
- Department of Pathology, University Hospitals Cleveland Medical Center, Rainbow Babies and Children's Hospital, Case Western Reserve University School of Medicine, Cleveland, OH
| | - Mary Ann Mino
- American Red Cross Northern Ohio Region, Cleveland, OH
| | | | | | - Connie Piccone
- Department of Pediatric Hematology and Oncology, University Hospitals Cleveland Medical Center and Rainbow Babies and Children's Hospital, Case Western Reserve University School of Medicine, Cleveland, OH
| | - Katharine A Downes
- Department of Pathology, University Hospitals Cleveland Medical Center, Rainbow Babies and Children's Hospital, Case Western Reserve University School of Medicine, Cleveland, OH
| |
Collapse
|
24
|
Tsering D, Chen C, Ye J, Han Z, Jing BQ, Liu XW, Chen X, Wang F, Ling P, Cao H. Enzymatic synthesis of human blood group P1 pentasaccharide antigen. Carbohydr Res 2016; 438:39-43. [PMID: 27960098 DOI: 10.1016/j.carres.2016.11.019] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2016] [Revised: 11/30/2016] [Accepted: 11/30/2016] [Indexed: 10/20/2022]
Abstract
The enzymatic synthesis of biologically important and structurally unique human P1PK blood group type P1 pentasaccharide antigen is described. This synthesis features a three-step sequential one-pot multienzyme (OPME) glycosylation for the stepwise enzymatic chain elongation of readily available lactoside acceptor with cheap and commercially available galactose and N-acetylglucosamine as donor precursors. This enzymatic synthesis provides an operationally simple approach to access P1 pentasaccharide and its structurally related Gb3 and P1 trisaccharide epitopes.
Collapse
Affiliation(s)
- Dawa Tsering
- National Glycoengineering Research Center, Shandong Provincial Key Laboratory of Carbohydrate Chemistry and Glycobiology, and School of Pharmaceutical Sciences, Shandong University, Jinan, 250012, China
| | - Congcong Chen
- National Glycoengineering Research Center, Shandong Provincial Key Laboratory of Carbohydrate Chemistry and Glycobiology, and School of Pharmaceutical Sciences, Shandong University, Jinan, 250012, China
| | - Jinfeng Ye
- National Glycoengineering Research Center, Shandong Provincial Key Laboratory of Carbohydrate Chemistry and Glycobiology, and School of Pharmaceutical Sciences, Shandong University, Jinan, 250012, China
| | - Zhipeng Han
- National Glycoengineering Research Center, Shandong Provincial Key Laboratory of Carbohydrate Chemistry and Glycobiology, and School of Pharmaceutical Sciences, Shandong University, Jinan, 250012, China
| | - Bai-Qian Jing
- Department of Pharmacy, Qilu Hospital, Shandong University, Jinan, 250012, China.
| | - Xian-Wei Liu
- National Glycoengineering Research Center, Shandong Provincial Key Laboratory of Carbohydrate Chemistry and Glycobiology, and School of Pharmaceutical Sciences, Shandong University, Jinan, 250012, China
| | - Xi Chen
- Department of Chemistry, University of California, One Shields Avenue, Davis, CA, 95616, USA
| | - Fengshan Wang
- National Glycoengineering Research Center, Shandong Provincial Key Laboratory of Carbohydrate Chemistry and Glycobiology, and School of Pharmaceutical Sciences, Shandong University, Jinan, 250012, China; Key Laboratory of Chemical Biology of Natural Products (Ministry of Education), Institute of Biochemical and Biotechnological Drugs, Shandong University, Jinan, 250012, China
| | - Peixue Ling
- National Glycoengineering Research Center, Shandong Provincial Key Laboratory of Carbohydrate Chemistry and Glycobiology, and School of Pharmaceutical Sciences, Shandong University, Jinan, 250012, China; Shandong Academy of Pharmaceutical Science, Jinan, 250101, China
| | - Hongzhi Cao
- National Glycoengineering Research Center, Shandong Provincial Key Laboratory of Carbohydrate Chemistry and Glycobiology, and School of Pharmaceutical Sciences, Shandong University, Jinan, 250012, China; State Key Laboratory of Microbial Technology, Shandong University, Jinan, 250100, China.
| |
Collapse
|
25
|
Kaczmarek R, Mikolajewicz K, Szymczak K, Duk M, Majorczyk E, Krop-Watorek A, Buczkowska A, Czerwinski M. Evaluation of an amino acid residue critical for the specificity and activity of human Gb3/CD77 synthase. Glycoconj J 2016; 33:963-973. [PMID: 27538840 PMCID: PMC5149393 DOI: 10.1007/s10719-016-9716-9] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2015] [Revised: 06/30/2016] [Accepted: 07/14/2016] [Indexed: 02/03/2023]
Abstract
Human Gb3/CD77 synthase (α1,4-galactosyltransferase) is the only known glycosyltransferase that changes acceptor specificity because of a point mutation. The enzyme, encoded by A4GALT locus, is responsible for biosynthesis of Gal(α1-4)Gal moiety in Gb3 (CD77, Pk antigen) and P1 glycosphingolipids. We showed before that a single nucleotide substitution c.631C > G in the open reading frame of A4GALT, resulting in replacement of glutamine with glutamic acid at position 211 (substitution p. Q211E), broadens the enzyme acceptor specificity, so it can not only attach galactose to another galactose but also to N-acetylgalactosamine. The latter reaction leads to synthesis of NOR antigens, which are glycosphingolipids with terminal Gal(α1-4)GalNAc sequence, never before described in mammals. Because of the apparent importance of position 211 for enzyme activity, we stably transfected the 2102Ep cells with vectors encoding Gb3/CD77 synthase with glutamine substituted by aspartic acid or asparagine, and evaluated the cells by quantitative flow cytometry, high-performance thin-layer chromatography and real-time PCR. We found that cells transfected with vectors encoding Gb3/CD77 synthase with substitutions p. Q211D or p. Q211N did not express Pk, P1 and NOR antigens, suggesting complete loss of enzymatic activity. Thus, amino acid residue at position 211 of Gb3/CD77 synthase is critical for specificity and activity of the enzyme involved in formation of Pk, P1 and NOR antigens. Altogether, this approach affords a new insight into the mechanism of action of the human Gb3/CD77 synthase.
Collapse
Affiliation(s)
- Radoslaw Kaczmarek
- Laboratory of Glycoconjugate Immunochemistry, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland
| | - Katarzyna Mikolajewicz
- Laboratory of Glycoconjugate Immunochemistry, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland
- Confocal Microscopy Laboratory, Wroclaw Research Centre EIT+, Wroclaw, Poland
| | - Katarzyna Szymczak
- Laboratory of Glycoconjugate Immunochemistry, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland
| | - Maria Duk
- Laboratory of Glycoconjugate Immunochemistry, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland
| | - Edyta Majorczyk
- Laboratory of Glycoconjugate Immunochemistry, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland
- Institute of Physiotherapy, Faculty of Physiotherapy and Physical Education, Opole University of Technology, Opole, Poland
| | - Anna Krop-Watorek
- Department of Biotechnology and Molecular Biology, University of Opole, Opole, Poland
| | - Anna Buczkowska
- Laboratory of Glycoconjugate Immunochemistry, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland
- Institute of Biochemistry and Biophysics, Polish Academy of Sciences, Warsaw, Poland
| | - Marcin Czerwinski
- Laboratory of Glycoconjugate Immunochemistry, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland.
- Institute of Physiotherapy, Faculty of Physiotherapy and Physical Education, Opole University of Technology, Opole, Poland.
| |
Collapse
|
26
|
Dotz V, Wuhrer M. Histo-blood group glycans in the context of personalized medicine. Biochim Biophys Acta Gen Subj 2016; 1860:1596-607. [PMID: 26748235 PMCID: PMC7117023 DOI: 10.1016/j.bbagen.2015.12.026] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2015] [Revised: 12/29/2015] [Accepted: 12/30/2015] [Indexed: 12/12/2022]
Abstract
BACKGROUND A subset of histo-blood group antigens including ABO and Lewis are oligosaccharide structures which may be conjugated to lipids or proteins. They are known to be important recognition motifs not only in the context of blood transfusions, but also in infection and cancer development. SCOPE OF REVIEW Current knowledge on the molecular background and the implication of histo-blood group glycans in the prevention and therapy of infectious and non-communicable diseases, such as cancer and cardiovascular disease, is presented. MAJOR CONCLUSIONS Glycan-based histo-blood groups are associated with intestinal microbiota composition, the risk of various diseases as well as therapeutic success of, e.g., vaccination. Their potential as prebiotic or anti-microbial agents, as disease biomarkers and vaccine targets should be further investigated in future studies. For this, recent and future technological advancements will be of particular importance, especially with regard to the unambiguous structural characterization of the glycan portion in combination with information on the protein and lipid carriers of histo-blood group-active glycans in large cohorts. GENERAL SIGNIFICANCE Histo-blood group glycans have a unique linking position in the complex network of genes, oncodevelopmental biological processes, and disease mechanisms. Thus, they are highly promising targets for novel approaches in the field of personalized medicine. This article is part of a Special Issue entitled "Glycans in personalised medicine" Guest Editor: Professor Gordan Lauc.
Collapse
Affiliation(s)
- Viktoria Dotz
- Division of Bioanalytical Chemistry, VU University Amsterdam, Amsterdam, The Netherlands; Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, The Netherlands.
| | - Manfred Wuhrer
- Division of Bioanalytical Chemistry, VU University Amsterdam, Amsterdam, The Netherlands; Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden, The Netherlands
| |
Collapse
|
27
|
Human Gb3/CD77 synthase reveals specificity toward two or four different acceptors depending on amino acid at position 211, creating P(k), P1 and NOR blood group antigens. Biochem Biophys Res Commun 2016; 470:168-174. [PMID: 26773500 DOI: 10.1016/j.bbrc.2016.01.017] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2015] [Accepted: 01/04/2016] [Indexed: 11/21/2022]
Abstract
Human Gb3/CD77 synthase (α1,4-galactosyltransferase, P(k) synthase), encoded by A4GALT gene, is known for synthesis of Gal(α1-4)Gal moiety in globotriaosylceramide (Gb3Cer, CD77, P(k) blood group antigen), a glycosphingolipid of the globo series. Recently, it was shown that c.631C > G mutation in A4GALT, which causes p.Q211E substitution in the open reading frame of the enzyme, broadens the enzyme specificity, making it able also to synthesize Gal(α1-4)GalNAc moiety, which constitutes the defining terminal disaccharide of the NOR antigen (carried by two glycosphingolipids: NOR1 and NOR2). Terminal Gal(α1-4)Gal disaccharide is also present in another glycosphingolipid blood group antigen, called P1, which together with P(k) and NOR comprises the P1PK blood group system. Despite several attempts, it was never clearly shown that P1 antigen is synthesized by Gb3/CD77 synthase, leaving open an alternative hypothesis that there are two homologous α1,4-galactosyltransferases in humans. In this study, using recombinant Gb3/CD77 synthase produced in insect cells, we show that the consensus enzyme synthesizes both the P(k) and P1 antigens, while its p.Q211E variant additionally synthesizes the NOR antigen. This is the first direct biochemical evidence that Gb3/CD77 synthase is able to synthesize two different glycosphingolipid antigens: P(k) and P1, and when p.Q211E substitution is present, the NOR antigen is also synthesized.
Collapse
|
28
|
Abstract
Blood group antigens represent polymorphic traits inherited among individuals and populations. At present, there are 34 recognized human blood groups and hundreds of individual blood group antigens and alleles. Differences in blood group antigen expression can increase or decrease host susceptibility to many infections. Blood groups can play a direct role in infection by serving as receptors and/or coreceptors for microorganisms, parasites, and viruses. In addition, many blood group antigens facilitate intracellular uptake, signal transduction, or adhesion through the organization of membrane microdomains. Several blood groups can modify the innate immune response to infection. Several distinct phenotypes associated with increased host resistance to malaria are overrepresented in populations living in areas where malaria is endemic, as a result of evolutionary pressures. Microorganisms can also stimulate antibodies against blood group antigens, including ABO, T, and Kell. Finally, there is a symbiotic relationship between blood group expression and maturation of the gastrointestinal microbiome.
Collapse
Affiliation(s)
- Laura Cooling
- Department of Pathology, University of Michigan, Ann Arbor, Michigan, USA
| |
Collapse
|